Heparin and heparin-like glycosaminoglycans (HLGAGs) (HLGAGs)

Heparin and heparin-like glycosaminoglycans (HLGAGs) are complex, highly sulfated linear polysaccharides found on cell surfaces and in the extracellular matrix [PMID: 22431261]. They play critical roles in physiological processes by interacting with a wide array of proteins, including coagulation factors, growth factors, chemokines, and viral attachment proteins [PMID: 21833661]. In the context of anticoagulation, heparin acts as a catalyst to accelerate the inhibition of thrombin and factor Xa by antithrombin III [StatPearls: Heparin]. Beyond hematology, HLGAGs are involved in modulating cell signaling pathways essential for tumor growth, angiogenesis, and inflammatory responses [PMID: 26303407]. They also serve as co-receptors for various pathogens, making them significant targets for antiviral and anti-inflammatory therapeutic strategies [PMID: 32554444]. Therapeutic intervention often involves neutralizing these molecules with agents like protamine sulfate or using heparin-mimetics to compete for protein binding sites [DrugBank: Protamine]. These molecules are also central to the pathology of lysosomal storage diseases like mucopolysaccharidosis, where their accumulation leads to multi-organ dysfunction [PMID: 25568278].

Other names

Heparan sulfateHeparinoidsSulfated glycosaminoglycansHeparan sulfate proteoglycans (HSPGs)

Potentiation of antithrombin III to inhibit thrombin and Factor Xa, neutralization of anionic charge by cationic agents, and competitive inhibition of protein-glycosaminoglycan interactions [StatPearls: Heparin, PMID: 21833661].